- Home
- BTA vs BDTX Comparison
BTA vs BDTX Comparison
Compare BTA & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTA | BDTX |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.4M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BTA | BDTX |
|---|---|---|
| Price | $9.34 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.60 |
| AVG Volume (30 Days) | 21.9K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 5.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | N/A | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.43 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.59 | $1.20 |
| 52 Week High | $10.62 | $4.94 |
Technical Indicators
Market Signals| Indicator | BTA | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 33.50 |
| Support Level | $9.24 | $2.52 |
| Resistance Level | $9.39 | $2.69 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 31.25 | 17.44 |
Price Performance
Historical ComparisonAbout BTA BlackRock Long-Term Municipal Advantage Trust of Beneficial Interest
Blackrock Long-term Municipal AdtgTrust is a diversified closed-end investment trust. Its investment objective is to provide current income exempt from regular U.S. federal income tax. The fund, under normal market conditions, invests a majority of its managed assets in municipal obligations and derivative instruments with exposure to such municipal obligations, in each case that are expected to pay interest or income that is exempt from U.S. federal income tax. Its investment portfolio comprises dollar-weighted, long-term municipal bonds with a maturity of more than ten years at the time of investment. The fund's investments have exposure to various sectors such as Corporate, Health, County/City/Special District/School District, Transportation, Education, Utilities, State, Tobacco, etc.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.